Looking after the overlooked

Theratechnologies is a commercial-stage biopharmaceutical company. We currently market prescription products in the United States, Europe and Canada. Our commercialized products and our research pipeline focus on specialized therapies addressing unmet medical needs in HIV and oncology.

Most recent

May 15, 2020

Theratechnologies Unveils New Positive Data For Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers

May 12, 2020

Theratechnologies To Present At The RBC Capital Markets Global Healthcare Conference On May 19, 2020

April 27, 2020

Theratechnologies Announces New Positive Results For Two Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Ovarian Cancer

Making a difference

Theratechnologies makes a difference in the life of patients through the development and commercialization of products addressing niche therapeutic needs.

Our values


The Company operates in a highly competitive and regulated field. We must constantly be creative and resourceful in finding innovative solutions that enable the Company to make the right decisions in a timely manner.


There are many challenges in our field. Theratechnologies' employees do not shy away from a challenge and demonstrate resilience, drive and determination in finding innovative solutions and achieving the Company's goals.


We are fully committed to market innovative therapies for orphan medical conditions. Our commitment also translates to our shareholders by continuously ensuring the growth of the Company.

Our commercialized products

Theratechnologies currently commercializes three products in the field of HIV. Trogarzo® is approved in the United States and Europe. EGRIFTA SVTM is approved in the United States while EGRIFTA® is approved in the United States, Canada and Mexico.